Testosterone and male contraception.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
aheadofprint
Résumé
Rates of unintended pregnancy have remained relatively stagnant for many years, despite a broad array of female contraceptive options. Recent restrictions on access to abortion in some countries have increased the urgency for expanding contraceptive options. Increasing data suggest men are keen to utilize novel reversible male contraceptives. Despite decades of clinical research in male contraception, no reversible hormonal product currently exists. Nestorone/testosterone, among other novel androgens, shows promise to finally move to pivotal Phase 3 studies and introduction to the marketplace. Hormonal male contraception utilizes androgens or androgen-progestin combinations to exploit negative feedback that regulates the hypothalamic-pituitary-testicular axis. By suppressing release of gonadotropins, these agents markedly decrease endogenous testosterone production, lower intratesticular testosterone and suppress spermatogenesis. The addition of a progestin enhances the degree and speed of sperm suppression. The androgen component preserves a state of symptomatic eugonadism in the male. There is growing demand and acceptance of male contraceptive options in various forms. As these formulations progress through stages of drug development, regulatory oversight and communication with developers around safety and efficacy standards and garnering industry support for advancing the production of male contraceptives will be imperative.
Identifiants
pubmed: 39155802
doi: 10.1097/MED.0000000000000880
pii: 01266029-990000000-00103
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Nelson HD, Darney BG, Ahrens K, et al. Associations of unintended pregnancy with maternal and infant health outcomes: a systematic review and meta-analysis. JAMA 2022; 328:1714–1729.
Bearak J, Popinchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health 2020; 8:e1152–e1161.
Youssef H. The history of the condom. J R Soc Med 1993; 86:226–228.
Sundaram A, Vaughan B, Kost K, et al. Contraceptive failure in the United States: estimates from the 2006-2010 National Survey of Family Growth. Perspect Sex Reprod Health 2017; 49:7–16.
Patel AP, Smith RP. Vasectomy reversal: a clinical update. Asian J Androl 2016; 18:365–371.
Martin CW, Anderson RA, Cheng L, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 2000; 15:637–645.
Heinemann K, Saad F, Wiesemes M, et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005; 20:549–556.
Eberhardt J, van Wersch A, Meikle N. Attitudes towards the male contraceptive pill in men and women in casual and stable sexual relationships. J Fam Plann Reprod Healthcare 2009; 35:161–165.
Richard C, Pourchasse M, Freton L, et al. Male contraception: what do women think? Prog Urol 2022; 32:276–283.
Amann RP. The cycle of the seminiferous epithelium in humans: a need to revisit? J Androl 2008; 29:469–487.
Ly LP, Liu PY, Handelsman DJ. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum Reprod 2005; 20:1733–1740.
Coviello AD, Bremner WJ, Matsumoto AM, et al. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 2004; 25:931–938.
Matsumoto AM, Bremner WJ. Stimulation of sperm production by human chorionic gonadotropin after prolonged gonadotropin suppression in normal men. J Androl 1985; 6:137–143.
Finkelstein JS, O’Dea LS, Whitcomb RW, Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 1991; 73:621–628.
Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann Clin Biochem 2013; 50:95–107.
Thirumalai A, Page ST. Recent Developments in Male Contraception. Drugs 2019; 79:11–20.
Liu PY, Swerdloff RS, Anawalt BD, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 2008; 93:1774–1783.
Liu PY, Swerdloff RS, Christenson PD, et al. Hormonal Male Contraception Summit G. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367:1412–1420.
Nieschlag E. Clinical trials in male hormonal contraception. Contraception 2010; 82:457–470.
Wang C, Festin MP, Swerdloff RS. Male hormonal contraception: where are we now? Curr Obstet Gynecol Rep 2016; 5:38–47.
Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990; 336:955–959.
World Health Organization Task Force on Methods for the Regulation of Male F Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996; 65:821–829.
Thirumalai A, Page ST. Androgens in male contraception. Best Pract Res Clin Endocrinol Metab 2022; 36:101627.
McLachlan RI, McDonald J, Rushford D, et al. Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 2000; 62:73–78.
Turner L, Conway AJ, Jimenez M, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 2003; 88:4659–4667.
Gu YQ, Wang XH, Xu D, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003; 88:562–568.
Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 2009; 94:1910–1915.
Behre HM, Zitzmann M, Anderson RA, et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab 2016; 101:4779–4788.
Amory JK, Blithe DL, Sitruk-Ware R, et al. Design of an international male contraceptive efficacy trial using a self-administered daily transdermal gel containing testosterone and segesterone acetate (Nestorone). Contraception 2023; 124:110064.
Ilani N, Roth MY, Amory JK, et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 2012; 97:3476–3486.
Stahlman J, Britto M, Fitzpatrick S, et al. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. Curr Med Res Opin 2012; 28:281–290.
Yuen F, Wu S, Thirumalai A, et al. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology 2019; 7:235–243.
Pavlou SN, Brewer K, Farley MG, et al. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 1991; 73:1360–1369.
Tom L, Bhasin S, Salameh W, et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab 1992; 75:476–483.
Bagatell CJ, Matsumoto AM, Christensen RB, et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 1993; 77:427–432.
Behre HM, Kliesch S, Lemcke B, et al. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this nonaromatizable androgen alone. Hum Reprod 2001; 16:2570–2577.
Page ST, Amory JK, Anawalt BD, et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 2006; 91:4374–4380.
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020; 382:2187–2196.
Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol 2020; 12:1756287220937232.
LaMorte A, Kumar N, Bardin CW, Sundaram K. Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes in vitro. J Steroid Biochem Mol Biol 1994; 48:297–304.
Kumar N, Didolkar AK, Monder C, et al. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130:3677–3683.
Walton MJ, Kumar N, Baird DT, et al. 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl 2007; 28:679–688.
Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 2006; 147:3016–3026.
Attardi BJ, Hild SA, Koduri S, et al. The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. J Steroid Biochem Mol Biol 2010; 122:212–218.
Attardi BJ, Pham TC, Radler LC, et al. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol 2008; 110:214–222.
Attardi BJ, Marck BT, Matsumoto AM, et al. Long-term effects of dimethandrolone 17beta-undecanoate and 11beta-methyl-19-nortestosterone 17beta-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl 2011; 32:183–192.
Hild SA, Attardi BJ, Koduri S, et al. Effects of synthetic androgens on liver function using the rabbit as a model. J Androl 2010; 31:472–481.
Hild SA, Marshall GR, Attardi BJ, et al. Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis). Endocrinology 2007; 148:1784–1796.
Ayoub R, Page ST, Swerdloff RS, et al. Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive. Andrology 2017; 5:278–285.
Thirumalai A, Ceponis J, Amory JK, et al. Effects of 28 days of oral dimethandrolone undecanoate in healthy men: a prototype male pill. J Clin Endocrinol Metab 2019; 104:423–432.
Thirumalai A, Yuen F, Amory JK, et al. Dimethandrolone undecanoate, a novel, nonaromatizable androgen, increases P1NP in healthy men over 28 days. J Clin Endocrinol Metab 2021; 106:e171–e181.
Yuen F, Thirumalai A, Pham C, et al. Daily oral administration of the novel androgen 11beta-MNTDC markedly suppresses serum gonadotropins in healthy men. J Clin Endocrinol Metab 2020; 105:e835–e847.
Yuen F, Thirumalai A, Fernando FA, et al. Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11beta-MNTDC in healthy men. Andrology 2021; 9:1526–1539.
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023; 389:107–117.
Bhasin S, Seidman S, Travison TG, et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. J Clin Endocrinol Metab 2024; 109:1814–1826.
Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev 2018; 39:369–386.
Reynolds-Wright JJ, Cameron NJ, Anderson RA. Will men use novel male contraceptive methods and will women trust them? A systematic review. J Sex Res 2021; 58:838–849.
Soufir JC, Meduri G, Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 2011; 26:1708–1714.